Radiation boost may improve immunotherapy for esophageal cancer
NCT ID NCT05978193
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding low-dose or standard radiotherapy to the usual combination of immunotherapy (anti-PD-1) and chemotherapy can help people with metastatic esophageal squamous cell carcinoma. About 100 adults who have not had prior treatment will participate. The goal is to see if the radiation helps control the cancer longer without causing too many side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Ruijin Hospital
RECRUITINGShanghai, 200020, China
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Can Real-World data improve esophageal cancer care in africa?